Spectral Medical (EDT) Q2 2024 earnings summary

Executive summary

• Focused on developing and commercializing the PMX therapy for septic shock, with ongoing legacy reagent sales.

• Revenue for the six months ended June 30, 2024 was $1,139,000, up from $836,000 year-over-year.

• Net loss for the six months ended June 30, 2024 was $8,562,000, compared to $5,377,000 for the same period last year.

• Company continues to face material uncertainty regarding its ability to continue as a going concern, dependent on FDA approval and additional funding.

Financial highlights

• Cash balance at June 30, 2024 was $7,536,000, up from $2,952,000 at December 31, 2023.

• Revenue for Q2 2024 was $471,000, compared to $306,000 in Q2 2023.

• Operating expenses for the six months ended June 30, 2024 totaled $9,698,000, up from $6,219,000 year-over-year.

• Net cash used in operating activities for the six months ended June 30, 2024 was $3,620,000, compared to $5,588,000 in the prior year.

• Convertible notes payable (net) increased to $12,491,000 at June 30, 2024 from $7,940,000 at December 31, 2023.

Outlook and guidance

• Continued focus on obtaining FDA approval for PMX and commercializing the product.

• Additional capital will be required to fund clinical, regulatory, and commercialization activities.

• Management highlights material uncertainty about the company's ability to continue as a going concern.